PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Methylprednisolone

Drugs in development · updated 30 October 2026

Methylprednisolone: clinical trials and development status

Other names and codes: Medrol

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Methylprednisolone is in 99 active clinical trials (recruiting or ongoing, phases I–III) for 96 diseases. The most advanced phase is III.

99Active trials
IIIMost advanced phase
96Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Methylprednisolone and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 96 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Multiple myelomaIII5NCT04270409
Burkitt lymphomaIII4NCT03007147
Community-acquired pneumoniaIII4NCT07152600
Ischemic strokeIII4NCT06360458
Multiple sclerosisIII4NCT04544436
ColitisIII3NCT05947669
Diffuse large B-cell lymphomaIII3NCT06717347
Lupus nephritisIII3NCT04221477
Precursor T-cell lymphoblastic leukemiaIII3NCT03007147
Relapsing-remitting multiple sclerosisIII3NCT04544436
Acute biphenotypic leukaemiaIII2NCT03007147
Chronic progressive multiple sclerosisIII2NCT04688788
Optic nerve diseaseIII2NCT07623668
Precursor lymphoblastic lymphoma/leukemiaIII2NCT03007147
Prostatic NeoplasmsII–III2NCT04787744
Systemic lupus erythematosusIII2NCT04963296
Adenoviridae infectionsIII1NCT07152600
Adenovirus infectionIII1NCT07152600
Brain NeoplasmsII–III1NCT07542288
BursitisIII1NCT06848374
Chronic lymphocytic leukemiaIII1NCT06970743
Cluster headacheIII1NCT05324748
Diabetes insipidusIII1NCT05139849
DizzinessIII1NCT05851508
ErythemaIII1NCT06266221
Erythema multiformeIII1NCT06266221
Hearing LossIII1NCT05851508
InfluenzaIII1NCT07351500
IschemiaIII1NCT04873583
Left ventricular dysfunctionIII1NCT06522100

Everything on Methylprednisolone

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch